Contract Pharma Staff09.24.20
Sygnature Discovery, an integrated discovery and pre-clinical solutions provider, has expanded its DMPK capabilities and expertise with the acquisition of XenoGesis, an independent laboratory-based CRO specializing in pre-clinical DMPK, quantitative bioanalysis, in vitro pharmacology and expert interpretation.
This latest acquisition by Sygnature serves to meet both an increasing demand for its services and boost the company’s reach into the pre-clinical space.
This acquisition effectively doubles the size of Sygnature’s DMPK department (established in 2015), broadening Sygnature’s discovery and development expertise, complementing its existing service-offering and adding new skills and capabilities.
"Our ultimate mission at Sygnature is to help create life-changing drugs for patients that have made it through the drug discovery and development process, and we recognise the central role that DMPK plays in that journey,” commented Dr. Simon Hirst, CEO and founder at Sygnature Discovery. "We have always had tremendous respect for the work that XenoGesis does, and have a strong history of collaboration with them over the years. We are thrilled at this opportunity to build on the capabilities of both companies and enrich our service-offering going forward together."
The companies are both located at BioCity in Nottingham, UK, fitting well with Sygnature’s driving ethos of having co-located, multi-disciplinary teams of expert research scientists, working efficiently together, facilitating seamless drug discovery and creating innovative solutions for its partners
“Sygnature and XenoGesis have always had a superb working relationship and been closely aligned in our culture and aspirations. From the start, both companies have focused on world-class science, insightful data interpretation, and creating genuine partnerships with our customers,” said Dr. Richard Weaver, CEO and founder at XenoGesis. "Therefore, this step feels like a very natural one, and we are very excited about what we can accomplish together in helping accelerate our customers’ projects towards the clinic. My team and I are looking forward to joining forces with Sygnature."
This latest acquisition by Sygnature serves to meet both an increasing demand for its services and boost the company’s reach into the pre-clinical space.
This acquisition effectively doubles the size of Sygnature’s DMPK department (established in 2015), broadening Sygnature’s discovery and development expertise, complementing its existing service-offering and adding new skills and capabilities.
"Our ultimate mission at Sygnature is to help create life-changing drugs for patients that have made it through the drug discovery and development process, and we recognise the central role that DMPK plays in that journey,” commented Dr. Simon Hirst, CEO and founder at Sygnature Discovery. "We have always had tremendous respect for the work that XenoGesis does, and have a strong history of collaboration with them over the years. We are thrilled at this opportunity to build on the capabilities of both companies and enrich our service-offering going forward together."
The companies are both located at BioCity in Nottingham, UK, fitting well with Sygnature’s driving ethos of having co-located, multi-disciplinary teams of expert research scientists, working efficiently together, facilitating seamless drug discovery and creating innovative solutions for its partners
“Sygnature and XenoGesis have always had a superb working relationship and been closely aligned in our culture and aspirations. From the start, both companies have focused on world-class science, insightful data interpretation, and creating genuine partnerships with our customers,” said Dr. Richard Weaver, CEO and founder at XenoGesis. "Therefore, this step feels like a very natural one, and we are very excited about what we can accomplish together in helping accelerate our customers’ projects towards the clinic. My team and I are looking forward to joining forces with Sygnature."
